Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Kasliwal

Neurological Surgery Chicago, IL Medical Doctor

NPI 1306159272 CMS profile 1167930

1725 W Harrison St, Suite 1115, Rush University Medical Center, Chicago, IL 60612

Open in the dashboard

General payments

$9,529

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manish Kasliwal of Chicago, IL is reported in the CMS Open Payments database as having received $9,529 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,148 27
2024 General $3,063 39
2023 General $1,231 22
2022 General $1,469 24
2021 General $217 4
2020 General $185 2
2019 General $1,216 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Kasliwal
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Manish Kasliwal were reported at $2,148. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Manish Kasliwal Neurological Surgery median Middle half National median
2019 $1,216 $582 $138–$3,006 $163
2020 $185 $294 $76–$2,174 $114
2021 $217 $387 $105–$2,432 $132
2022 $1,469 $542 $139–$2,989 $149
2023 $1,231 $534 $145–$2,697 $160
2024 $3,063 $574 $155–$3,046 $164
2025 $2,148 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,406 63 payments
  2. Globus Medical, Inc. $2,335 30 payments
  3. Nexus Medical Technologies LLC $919 3 payments
  4. NuVasive, Inc. $550 11 payments
  5. icotec Medical Inc. $406 5 payments
  6. Arthrex, Inc. $288 3 payments
  7. Medtronic USA, Inc. $233 4 payments
  8. Arteriocyte Medical Systems, Inc. $162 2 payments
  9. Cerapedics, Inc. $136 1 payment
  10. Ascendis Pharma, Inc. $55 2 payments
  11. Other $40 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,126 25 payments
  2. Food and Beverage $4,403 101 payments
Products named General payments · program years 2019–2025
  1. STEALTHSTATION S8 PLATFORM $2,213 15 payments
  2. FORTIFY $1,024 3 payments
  3. CD HORIZON SPINAL SYSTEM $899 11 payments
  4. UNID_PASS $779 24 payments
  5. ExcelsiusGPS Robotic Navigation System $715 6 payments
  6. KONG-TL VBR E, EXPANDABLE BODY, L, 19 MM X 27 - 37 MM $406 5 payments
  7. VADER PEDICLE SYSTEM, ROD, CARBON/PEEK, CURVED, 6.0 R450 X 200 MM $406 5 payments
  8. KONG-TL VBR, END PLATE, RECTANGULAR, M AND SCREW, 12 X 33 MM $406 5 payments
  9. KONG-TL VBR, END PLATE, ROUND, L AND SCREW, 12 X 43 MM $406 5 payments
  10. VADER PEDICLE SYSTEM 6.0, SCREW, CARBON/PEEK, POLYAX., FEN., O 5.5 X 45 MM $406 5 payments
  11. Other $2,579 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

64

Median for Neurosurgery: 83

Drug cost

$253

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 42 $131
Cyclobenzaprine Hcl Generic 22 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$90,109

Medicare's payments for the services billed

Medicare patients

181

Average age 74

Services billed

344

96 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 34%
Depression 32%
Chronic kidney disease 23%
COPD 22%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record